<!DOCTYPE html>

<html lang="en" data-theme="light">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Antirheumatoid & Antigout Drugs - Essentials of Medical Pharmacology</title>
    <link rel="preconnect" href="https://fonts.googleapis.com">
    <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
    <link
        href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&family=Source+Serif+4:opsz,wght@8..60,400;8..60,600&display=swap"
        rel="stylesheet">

    <link rel="stylesheet" href="../styles/main.css">

    <script>
        MathJax = {
            tex: {
                inlineMath: [['$', '$'], ['\\(', '\\)']],
                displayMath: [['$$', '$$'], ['\\[', '\\]']],
                processEscapes: true,
                processEnvironments: true
            },
            svg: { fontCache: 'global' },
            options: {
                skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
            }
        };
    </script>

    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>

</head>

<body>
    <a href="#main-content" class="skip-link">Skip to main content</a>

    <button class="theme-toggle" id="theme-toggle" aria-label="Toggle dark mode">
        <span class="theme-toggle-icon light-icon">‚òÄÔ∏è</span>
        <span class="theme-toggle-icon dark-icon">üåô</span>
    </button>

    <div class="reading-progress-container">
        <div class="reading-progress-bar" id="reading-progress"></div>
    </div>

    <!-- Floating TOC -->

    <nav class="floating-toc" id="floating-toc">
        <div class="floating-toc-header">
            <span>üìë</span> Table of Contents
        </div>
        <ul class="floating-toc-list">
            <li><a href="#ra-intro">Antirheumatoid Drugs (DMARDs)</a></li>
            <li><a href="#nonbiologic-dmards">Nonbiological DMARDs</a></li>
            <li><a href="#biologic-dmards">Biological Agents</a></li>
            <li><a href="#corticosteroids">Corticosteroids in RA</a></li>
            <li><a href="#gout-acute">Drugs for Acute Gout</a></li>
            <li><a href="#gout-chronic">Chronic Gout: Uricosurics</a></li>
            <li><a href="#gout-synthesis">Chronic Gout: Synthesis Inhibitors</a></li>
            <li><a href="#case-study">Problem Directed Study</a></li>
        </ul>
    </nav>

    <div class="page-wrapper">
        <div class="container">
            <article class="document-article">
                <header class="document-header">
                    <div class="header-badge">
                        <span>ü¶¥</span>
                        <span>Topic 16</span>
                    </div>
                    <h1 class="document-title">Antirheumatoid and Antigout Drugs</h1>
                    <div class="title-meta">
                        <div class="meta-item">
                            <span>üìö</span>
                            <span>Autacoids and Related Drugs</span>
                        </div>
                        <div class="meta-item">
                            <span>‚è±Ô∏è</span>
                            <span>40 min read</span>
                        </div>
                    </div>
                </header>

                <main id="main-content" class="content-wrapper">
                    <!-- Section 1: RA Intro -->
                    <section class="content-section" id="ra-intro">
                        <div class="section-header">
                            <div class="section-number">01</div>
                            <h2 class="section-title">
                                <span class="title-icon">üõë</span>
                                Antirheumatoid Drugs
                            </h2>
                        </div>

                        <div class="content-card">
                            <p>These are drugs which (except corticosteroids), can suppress the rheumatoid process,
                                bring about a remission and retard disease progression, but do not have nonspecific
                                antiinflammatory or analgesic action. They are used in rheumatoid arthritis (RA) in
                                addition to NSAIDs, and are also referred to as <strong>disease modifying antirheumatic
                                    drugs (DMARDs)</strong> or <strong>slow acting antirheumatic drugs
                                    (SAARDs)</strong>.</p>
                            <p>Rheumatoid arthritis (RA) is an autoimmune disease in which there is joint inflammation,
                                synovial proliferation and destruction of articular cartilage. Immune complexes composed
                                of IgM activate complement and release cytokines (mainly TNF $\alpha$ and IL-1) which
                                are chemotactic for neutrophils.</p>

                            <div class="callout callout--info">
                                <div class="callout-header">
                                    <span class="callout-icon">üéØ</span>
                                    <h4 class="callout-title">Goals of Drug Therapy</h4>
                                </div>
                                <div class="callout-content">
                                    <ul class="enhanced-list">
                                        <li class="list-item">Ameliorate pain, swelling and joint stiffness.</li>
                                        <li class="list-item">Prevent articular cartilage damage and bony erosions.</li>
                                        <li class="list-item">Preserve joint function and prevent deformity.</li>
                                    </ul>
                                </div>
                            </div>
                        </div>
                    </section>

                    <!-- Section 2: Nonbiological DMARDs -->
                    <section class="content-section" id="nonbiologic-dmards">
                        <div class="section-header">
                            <div class="section-number">02</div>
                            <h2 class="section-title">
                                <span class="title-icon">üíä</span>
                                Nonbiological Drugs
                            </h2>
                        </div>

                        <div class="content-card">
                            <h3>Methotrexate (Mtx)</h3>
                            <p>This dihydrofolate reductase inhibitor has prominent immunosuppressant and
                                antiinflammatory property. Beneficial effects in RA are probably related to inhibition
                                of cytokine production, chemotaxis and cell-mediated immune reaction.</p>
                            <ul class="enhanced-list">
                                <li class="list-item"><strong>Status:</strong> Mtx is now the DMARD of first choice and
                                    the standard treatment for most patients.</li>
                                <li class="list-item"><strong>Dose:</strong> Oral low-dose (7.5‚Äì15 mg) weekly. Onset of
                                    symptom relief is relatively rapid (3‚Äì6 weeks).</li>
                                <li class="list-item"><strong>Adverse Effects:</strong> Oral ulceration, g.i. upset,
                                    dose dependent progressive liver damage (cirrhosis) with prolonged therapy,
                                    increased chest infection. Contraindicated in pregnancy.</li>
                            </ul>

                            <h3>Sulfasalazine</h3>
                            <p>It is a compound of sulfapyridine and 5-amino salicylic acid (5-ASA). In RA,
                                sulfapyridine split off in the colon and absorbed systemically appears to be the active
                                moiety. Efficacy is modest; used as a second line drug or combined with Mtx.</p>

                            <h3>Hydroxychloroquine / Chloroquine</h3>
                            <p>These antimalarial drugs induce remission in upto 50% patients but take 3‚Äì6 months. Their
                                advantage is relatively low toxicity, but efficacy is also low; bony erosions are not
                                prevented.
                                <strong>Toxicity:</strong> Retinal damage and corneal opacity are the most disturbing;
                                eye checkup is essential.
                            </p>

                            <h3>Leflunomide</h3>
                            <p>Inhibits dihydro-orotate dehydrogenase and pyrimidine synthesis in actively dividing
                                cells. Efficacy comparable to Mtx. Active metabolite has a very long $t_{1/2}$ (2‚Äì3
                                weeks). Hepatotoxic potential.</p>

                            <h3>Tofacitinib</h3>
                            <p>A new synthetic JAK-3 and JAK-1 kinase inhibitor for severe RA not responding to Mtx.
                                Interferes with JAK-STAT signaling.</p>
                        </div>
                    </section>

                    <!-- Section 3: Biological Agents -->
                    <section class="content-section" id="biologic-dmards">
                        <div class="section-header">
                            <div class="section-number">03</div>
                            <h2 class="section-title">
                                <span class="title-icon">üß¨</span>
                                Biological Agents
                            </h2>
                        </div>

                        <div class="content-card">
                            <p>Recombinant proteins/monoclonal antibodies that bind to and inhibit cytokines, especially
                                TNF $\alpha$ or IL-1. Used as reserve drugs for severe refractory disease.</p>

                            <h3>TNF $\alpha$ Inhibitors</h3>
                            <p>TNF $\alpha$ plays a key role in the inflammatory cascade. Inhibitors suppress macrophage
                                and T-cell function.</p>
                            <div class="table-responsive">
                                <table class="comparison-table">
                                    <thead>
                                        <tr>
                                            <th>Drug</th>
                                            <th>Nature</th>
                                            <th>Administration</th>
                                        </tr>
                                    </thead>
                                    <tbody>
                                        <tr>
                                            <td><strong>Etanercept</strong></td>
                                            <td>Recombinant fusion protein (TNF-receptor + Fc of IgG)</td>
                                            <td>s.c. weekly</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Infliximab</strong></td>
                                            <td>Chimeral monoclonal antibody</td>
                                            <td>i.v. infusion every 4-8 weeks</td>
                                        </tr>
                                        <tr>
                                            <td><strong>Adalimumab</strong></td>
                                            <td>Recombinant human monoclonal antibody</td>
                                            <td>s.c. every 2 weeks</td>
                                        </tr>
                                    </tbody>
                                </table>
                            </div>
                            <p><strong>Adverse Effects:</strong> Increased susceptibility to opportunistic infections
                                (tuberculosis, pneumocystis pneumonia).</p>

                            <h3>Other Agents</h3>
                            <ul class="enhanced-list">
                                <li class="list-item"><strong>Abatacept:</strong> Fusion protein inhibiting T-cell
                                    costimulation (binds CD80/86).</li>
                                <li class="list-item"><strong>Rituximab:</strong> Monoclonal antibody depleting
                                    B-lymphocytes.</li>
                                <li class="list-item"><strong>Anakinra:</strong> Recombinant IL-1 receptor antagonist.
                                </li>
                            </ul>
                        </div>
                    </section>

                    <!-- Section 4: Corticosteroids -->
                    <section class="content-section" id="corticosteroids">
                        <div class="section-header">
                            <div class="section-number">04</div>
                            <h2 class="section-title">
                                <span class="title-icon">‚ö°</span>
                                Corticosteroids in RA
                            </h2>
                        </div>

                        <div class="content-card">
                            <p>Glucocorticoids have potent immunosuppressant and antiinflammatory activity. Symptomatic
                                relief is prompt and marked, but they do not arrest the rheumatoid process.</p>
                            <p><strong>Strategies:</strong></p>
                            <ul>
                                <li>Low doses (5‚Äì7.5 mg prednisolone) to supplement NSAIDs ("bridge therapy").</li>
                                <li>High doses for short periods in severe systemic manifestations (vasculitis).</li>
                                <li>Intraarticular injection for single joint involvement.</li>
                            </ul>
                        </div>
                    </section>

                    <!-- Section 5: Gout -->
                    <section class="content-section" id="gout-acute">
                        <div class="section-header">
                            <div class="section-number">05</div>
                            <h2 class="section-title">
                                <span class="title-icon">üî•</span>
                                Drugs for Acute Gout
                            </h2>
                        </div>

                        <div class="content-card">
                            <p>Gout is a metabolic disorder characterized by hyperuricaemia (plasma urate $> 6$ mg/dl)
                                and precipitation of urate crystals in joints.</p>

                            <h3>1. NSAIDs</h3>
                            <p>Strong antiinflammatory drugs like <strong>Naproxen, Piroxicam, Diclofenac, Indomethacin
                                    or Etoricoxib</strong> are given in high doses. They are quite effective in
                                terminating the attack (12‚Äì24 hours). <strong>Preferred over colchicine</strong> due to
                                better tolerability.</p>

                            <h3>2. Colchicine</h3>
                            <p>Alkaloid from <em>Colchicum autumnale</em>. Neither analgesic nor antiinflammatory
                                generally, but specifically suppresses gouty inflammation.</p>
                            <div class="callout callout--info">
                                <div class="callout-header">
                                    <span class="callout-icon">üîÑ</span>
                                    <h4 class="callout-title">Mechanism</h4>
                                </div>
                                <div class="callout-content">
                                    <p>Binds to fibrillar protein <strong>tubulin</strong> and inhibits granulocyte
                                        migration into the inflamed joint. Also inhibits release of chemotactic factors
                                        and glycoprotein.</p>
                                </div>
                            </div>
                            <p><strong>Toxicity:</strong> Nausea, vomiting, watery/bloody <strong>diarrhoea</strong>
                                (dose limiting). Risk of kidney damage and CNS depression in overdose.</p>

                            <h3>3. Corticosteroids</h3>
                            <p>Intraarticular injection of soluble steroid (e.g., triamcinolone) or systemic steroids
                                for patients not tolerating NSAIDs/colchicine.</p>
                        </div>
                    </section>

                    <!-- Section 6: Chronic Gout -->
                    <section class="content-section" id="gout-chronic">
                        <div class="section-header">
                            <div class="section-number">06</div>
                            <h2 class="section-title">
                                <span class="title-icon">üöΩ</span>
                                Chronic Gout: Uricosurics
                            </h2>
                        </div>

                        <div class="content-card">
                            <p>Used to treat chronic gout/hyperuricaemia by increasing uric acid excretion.</p>

                            <h3>Probenecid</h3>
                            <p>A highly lipid-soluble organic acid. Competitively blocks active transport of organic
                                acids by OATP in renal tubules.</p>
                            <ul class="enhanced-list">
                                <li class="list-item"><strong>Mechanism:</strong> Inhibits active reabsorption of uric
                                    acid (which is largely reabsorbed). Net effect: increased excretion.</li>
                                <li class="list-item"><strong>Interactions:</strong> Inhibits excretion of penicillin,
                                    cephalosporins, methotrexate. Aspirin blocks uricosuric action.</li>
                                <li class="list-item"><strong>Contraindication:</strong> Renal insufficiency, renal
                                    stones.</li>
                            </ul>
                        </div>
                    </section>

                    <!-- Section 7: Synthesis Inhibitors -->
                    <section class="content-section" id="gout-synthesis">
                        <div class="section-header">
                            <div class="section-number">07</div>
                            <h2 class="section-title">
                                <span class="title-icon">üõë</span>
                                Chronic Gout: Synthesis Inhibitors
                            </h2>
                        </div>

                        <div class="content-card">
                            <h3>Allopurinol</h3>
                            <p>Hypoxanthine analogue. Both allopurinol and its metabolite <strong>alloxanthine</strong>
                                are inhibitors of <strong>Xanthine Oxidase</strong>, the enzyme responsible for uric
                                acid synthesis.</p>
                            <ul class="enhanced-list">
                                <li class="list-item"><strong>Action:</strong> Lowers plasma uric acid; increases
                                    hypoxanthine/xanthine (which are more soluble). Tophi disappear, nephropathy halted.
                                </li>
                                <li class="list-item"><strong>Drug of Choice:</strong> For chronic gout (overproducers
                                    and underexcretors).</li>
                                <li class="list-item"><strong>Interaction:</strong> Inhibits degradation of
                                    <strong>6-mercaptopurine</strong> and <strong>azathioprine</strong> (doses must be
                                    reduced to 1/3).</li>
                                <li class="list-item"><strong>Adverse Effects:</strong> Hypersensitivity (rashes,
                                    fever), Stevens-Johnson syndrome (rare).</li>
                                <li class="list-item"><strong>Caution:</strong> Do not start during acute attack. Cover
                                    with NSAIDs/colchicine during initial months to prevent precipitation of acute
                                    attacks.</li>
                            </ul>

                            <h3>Febuxostat</h3>
                            <p>Nonpurine xanthine oxidase inhibitor. Alternative to allopurinol. Can cause liver damage.
                            </p>

                            <h3>Pegloticase</h3>
                            <p>Recombinant uricase enzyme (oxidizes uric acid to allantoin). Used for refractory gout.
                            </p>
                        </div>
                    </section>

                    <!-- Section 8: Case Study -->
                    <section class="content-section" id="case-study">
                        <div class="section-header">
                            <div class="section-number">08</div>
                            <h2 class="section-title">
                                <span class="title-icon">ü§î</span>
                                Problem Directed Study
                            </h2>
                        </div>

                        <div class="content-card">
                            <div class="callout callout--note">
                                <div class="callout-header">
                                    <span class="callout-icon">üìù</span>
                                    <h4 class="callout-title">Case 15.1</h4>
                                </div>
                                <div class="callout-content">
                                    <p>A 44-year-old lady with rheumatoid arthritis (RA) for 8 months is on Diclofenac
                                        and Pantoprazole. Symptoms are increasing, ESR and CRP are raised. Diagnosed as
                                        active RA.</p>
                                    <p><strong>(a) NSAID Status:</strong> Increasing diclofenac or substituting it will
                                        <strong>not</strong> be adequate. NSAIDs only provide symptomatic relief and do
                                        not arrest the disease process (bony erosions/joint destruction).</p>
                                    <p><strong>(b) Additional Drug:</strong> A <strong>DMARD</strong> (Disease Modifying
                                        Antirheumatic Drug) must be started immediately. <strong>Methotrexate</strong>
                                        is the first choice standard treatment. It arrests the immune-inflammatory
                                        process.</p>
                                    <p><strong>(c) Pre-requisites & Benefits:</strong> Check liver function, kidney
                                        function, and blood counts (bone marrow) before prescribing Methotrexate.
                                        Benefits (relief of pain/swelling, retardation of joint damage) are expected
                                        after <strong>3-6 weeks</strong>.</p>
                                    <p><strong>(d) Pantoprazole:</strong> It was prescribed to prevent NSAID-induced
                                        gastric injury. It should be <strong>continued</strong> as long as she takes the
                                        NSAID.</p>
                                </div>
                            </div>
                        </div>
                    </section>

                </main>

                <nav class="document-nav">
                    <div class="nav-container">
                        <a href="topic-15-nsaids.html" class="nav-button nav-button--large nav-button--previous">
                            <div class="nav-label">Previous</div>
                            <div class="nav-title">NSAIDs & Antipyretics</div>
                        </a>

                        <div class="document-progress">
                            <div class="progress-indicator">
                                <span>16</span>
                                <span class="progress-separator">/</span>
                                <span>20</span>
                            </div>
                            <div class="progress-bar-container">
                                <div class="progress-bar-fill" style="width: 80%;"></div>
                            </div>
                            <div class="progress-label">Topic Progress</div>
                        </div>

                        <a href="topic-17-respiratory.html" class="nav-button nav-button--large nav-button--next">
                            <div class="nav-label">Next</div>
                            <div class="nav-title">Respiratory System Drugs</div>
                        </a>
                    </div>
                </nav>
            </article>
        </div>
    </div>

    <script src="../js/theme.js"></script>

    <script src="../js/navigation.js"></script>

    <script src="../js/interactions.js"></script>

</body>

</html>